Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


In this issue


SPRINT, the study that concluded that ‘intensive’ blood pressure lowering provides evidence of benefits for an even lower systolic blood pressure target than that currently recommended, should be reported with caution by the media

Why sprinting to change clinical practice guidelines on blood pressure treatment is prematureSubscription


Caution is required when the media reports on high profile medical studies.


Review of tramadol use within NHS Scotland following reclassificationSubscription

By Audrey Thompson

After growing reports of misuse and harm, including increased implication in drug-related deaths, the Advisory Council on the Misuse of Drugs recommended that tramadol should be reclassified as a class C, Schedule 3 drug. This was enacted in June 2014.

Yellow card champions to help increase reporting of adverse drug reactionsSubscription

By , , , ,

The Yellow Card Scheme is vital in helping the Medicines and Healthcare products Regulatory Agency (MHRA) monitor the safety of medicines and vaccines that are on the market. The Yellow Card Centre Wales (YCC Wales) is one of five regional adverse drug reaction (ADR) monitoring centres acting on behalf of the MHRA.

CPD article

Targeted treatments for symptoms of selected behavioural disorders

Chronic tic disorders: diagnosis, treatment and managementSubscription

By ,

How different types of tic disorders are diagnosed and the appropriate therapeutic options for their management, with a focus on Tourette syndrome.


Statins and other cholesterol-lowering drugs are increasingly being used for primary prevention of atherosclerotic cardiovascular disease. In the image, micrograph of cholesterol crystals

Primary prevention of cardiovascular disease with statins: assessing the evidence base behind clinical guidanceSubscription


Statins and other cholesterol-lowering drugs are increasingly being used for primary prevention of atherosclerotic cardiovascular disease.

Inattention and hyperactive/impulsive symptoms are commonly seen in practice, with up to 6% of children meeting criteria for attention deficit hyperactivity disorder (ADHD). In the image, a crying child looks at the camera

Considerations in selecting pharmacological treatments for attention deficit hyperactivity disorder Subscription

By ,

Attention deficit hyperactivity disorder is highly prevalent and is associated with significant impairment across the lifespan.

Clinical Pharmacist

CP February 2016, Vol 8, No 2

Cover Story:

Factors that need to be considered when choosing psychopharmacological treatments for attention deficit hyperactivity disorder.

Read more…

Clinical Pharmacist

View previous issue

Clinical Pharmacist is a monthly, peer-reviewed journal that provides authoritative resources on the clinical management of disease in relation to medicines and up-to-date information about advances in pharmacy and drug development. Clinical Pharmacist publishes Review articles, Perspectives, evidence-based CPD articles and Practice Reports on topics from drug discovery to clinical pharmacology and pharmacy.

The international audience of Pharmaceutical Journal Publications consists of pharmacists, pharmaceutical scientists and healthcare professionals. The journal is available to 44,000 members of the Royal Pharmaceutical Society, as well as non-member individual subscribers and subscribing institutions.